She will champion the practice’s pharmaceutical efforts focused on biotechnology, pharmaceutical, specialty pharma, and orphan drug clients

International communications network, Finn Partners, has named Kristie Kuhl to the role of Senior Partner, Health, an appointment which will see her champion the practice’s pharmaceutical efforts focused on biotechnology, pharmaceutical, specialty pharma, and orphan drug clients.

The hire affirms the agency’s commitment to becoming a global leader in health communications across sectors which influence patient access to care. In the said capacity, she reports to Gil Bashe, Managing Partner and Global Health Practice Director of Finn Partners.

“Kristie has been on the frontlines addressing reimbursement, pricing, drug approvals, patient advocacy concerns, and helping clients navigate the social media landscape and other issues that dominate planning urgencies,” said Bashe.

“Clients have tapped her to lead numerous agency brand communications campaigns.  Additionally, she is a noted pioneer on bio-similars and orphan drugs communications.” According to him, supported by a law degree, Kuhl is sensitive to the regulatory environment, which is critical to navigating the health landscape.

The firm is counting on her insight to help communicators and marketers understand the diverse interests of payers, policymakers, providers as well as advocacy groups to create a unifying focus around patient access to medication. Prior to joining Finn Partners, she served as EVP at both Cohn & Wolfe and Makovsky & Company.

Furthermore, Kuhl has been in the forefront of many award-winning campaigns for blockbuster pharmaceutical products that reach millions and orphan drugs that improve the lives of thousands.  A standing commitment to make a difference in health, she volunteers within the patient community.

Translate »